An antisense oligonucleotide therapy showed efficacy as a prophylactic treatment for hereditary angioedema (HAE), the phase III OASIS-HAE trial showed. The least-squares mean time-normalized HAE ...

BioCryst Pharmaceuticals, Inc. today announced new real-world evidence showing that patients with hereditary angioedema (HAE) who have normal C1-inhibitor (HAE-nC1-INH) level and function had a ...

The latest announcement is out from Pharvaris ( (PHVS) ).

Please provide your email address to receive an email when new articles are posted on . One adverse event was recorded in the treatment group. An attack rate reduction of 93% was seen in the treatment ...

Among HAE patients who had treated a recent attack, the location and duration of the most recent attacks were similar between long-term prophylaxis (LTP) and on-demand only users Earlier on-demand ...

ZUG, Switzerland, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary ...

Long-term prophylaxis (LTP) is the cornerstone strategy to achieve disease control and improve patient quality of life(QoL), because many patients can become virtually attack-free with an acceptable ...

Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026Preparation of NDA ...

KalVista Pharmaceuticals (KALV) has been able to reach a targeted goal, which would be a specific number of targeted attacks so that it could complete an ongoing phase 3 trial, known as KONFIDENT. The ...

– ORLADEYO oral granules demonstrated early and sustained reduction in HAE attacks over one year of treatment in second interim analysis of APeX-P – – ORLADEYO oral granules are currently under review ...

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is one of the best upside stocks to buy now. On November 6, BioCryst Pharmaceuticals announced new data that showed the early and negative psychosocial ...

– Patient perspectives revealed frequent treatment delays, suboptimal clinical outcomes and substantial anxiety associated with injectable on-demand treatments, including those who received long-term ...